The purpose of this study was to investigate the additional benefit of single photon emission computed tomography/computed tomography (SPECT/CT) over whole-body planar bone scintigraphy (planar BS) and SPECT for the detection of bone metastases in breast cancer patients. 
INTRODUCTION
Breast cancer is the commonest cancer in females worldwide. The skeleton is the most common site of distant metastases in breast cancer. Bone is the first site of metastasis in 26% -50% of patients with metastatic breast cancer and it may develop during the course of the disease in 30% -85% of these patients (1) . There are various anatomical and functional imaging modalities for detecting and characterizing malignant bone involvement. Among them, planar bone scintigraphy has long been used as a valuable method for sensitively detecting or characterizing focal bone pathology; more recently, single-photon emission computed tomography (SPECT) has been used in this capacity (2) . Although functional bone imaging is a highly sensitive method, it lacks specificity (3). Therefore, radiography, CT, or MRI is frequently performed after bone scintigraphy to further characterize lesions evident on bone scans. The recently introduced novel hybrid SPECT/CT system offers a direct correlation of focal bone pathology with anatomic structures and therefore minimizes the number of equivocal findings. Screening for bone metastases and evaluation of the treatment response are the most frequent indications for bone scintigraphy using 99m Tc-methylene diphosphonate ( 99m Tc-MDP). Although the majority of bone metastases appear as hot spots, some appear as cold lesions. Benign lesions, such as hemangioma, may also appear as cold, making the differential diagnosis problematic. The differentiation of benign and malignant lesions can usually be achieved with CT coregistration and is a major advantage of SPECT/CT (4). The initial results for diagnosis of skeletal metastasis with this combined functional and morphologic system have been promising (5) . The prevalence and importance of accurate tumor staging makes carcinoma of the breast an interesting candidate for study. Furthermore, despite the increasing use of integrated SPECT/CT in the management of cancer patients, to our knowledge, the clinical utility of combined assessment of MDP avidity and morphologic changes in breast cancer metastases to bone has not been fully elucidated. Thus, the aim of the present study was to retrospectively investigate the additional benefit of MDP-SPECT/CT over SPECT and planar imaging in breast cancer patients.
MATERIALS AND METHODS

Patients
One hundred and twelve post-operative patients with histologically confirmed breast carcinoma and available information on primary treatment underwent whole body bone scintigraphy in the context of suspected metastasis at the Institute of Nuclear Medicine & Allied Sciences (INMAS), Mymensingh from December 2011 to August 2012. Approval from this institutional review board and written informed consent from the patients were obtained for this study. In 73 of the patients, planar BS showed no abnormal foci of radiotracer accumulation. In the remaining 39 patients, further work up by SPECT or SPECT/CT was necessary because of unclear findings of whole body planar BS. In 23 of these patients, a SPECT/CT scan was performed using a hybrid camera combining a dual-head gamma camera with dual-slice spiral CT scanner installed within the same gantry (Symbia T2; Siemens). In the other 16 patients, SPECT alone was performed, mainly because of the temporary technical defect of the SPECT/CT system. The 23 SPECT/CT studies were retrospectively evaluated by readers who were unaware of clinical pretest probability and the findings on the planar scintigraphy. The age range of patients was 44 -76 years (mean: 65 years).
The bone lesions were considered metastatic if an increase in tumor size was confirmed with follow up imaging studies, including bone scintigraphy, CT and MRI, with or without exacerbation of clinical symptoms. According to these criteria, 59 lesions were considered metastatic bone lesions, and 13 were considered benign lesions (eg, spondylarthrosis, osteophyte, fracture) in these 23 patients.
Image acquisition
Planar bone scintigraphy was the first to be performed. Planar images of the entire skeleton were acquired 2-3 h after intravenous injection of MBq) using a dual head gamma camera SPECT/CT system (Symbia T2; Siemens).After completion of planar scintigraphy, all 23 patients underwent SPECT with the gamma-camera used for scintigraphy. The detectors were positioned on the focal lesions localized with planar scintigraphy. The SPECT acquisition was performed in step-and-shoot mode over 360°(180°per head) with the patient supine. A 128 x 128 matrix was used, with a 5.6° angular step, an acquisition time of 12 s per frame, and a zoom factor ranging from 1 to 1.2 according to the individual patient. SPECT data were reconstructed with an ordered subset expectation maximization (OSEM) algorithm using e.soft reconstruction software (Siemens). Immediately after SPECT acquisition, CT scan was performed keeping the patients at the same position.
Unenhanced CT was acquired in helical mode with a table speed of 10.0 mm/rotation and a rotation time of 0.8 seconds. A voltage of 130 KV was used, and current was automatically adjusted in the range of 100-700 mA, depending on the setting of a noise index ranging from 24 to 33 and 5-mm slices were obtained. After reconstruction, SPECT images were corrected for attenuation and scatter. Both SPECT and CT axial 5-mm slices were generated using an e.soft Syngo MI ApplicationsVA60C (Siemens) for evaluation. The SPECT/CT images were also analyzed using 2-dimensional orthogonal reslicing in axial, sagittal, and coronal orientations. A maximum-intensity projection 3-dimensional display was generated to improve contrast enhancement of the images.
Image interpretation
Planar scintigraphy, SPECT and SPECT/CT images were evaluated blindly and separately: first the planar BS images, then SPECT images by two nuclear medicine physicians in consensus, and last the fused SPECT/CT images by a nuclear medicine physician and a radiologist in consensus.
Each site of abnormally increased uptake of 99m Tc-MDP was recorded and categorized as normal (no increased uptake), benign, malignant, or equivocal. Scintigraphic lesions were categorized as benign when they appeared as areas of low intensity increased tracer uptake or when they were located around joints. Vertebral lesions were considered malignant when they involved the posterior aspect of the vertebral body and pedicle or when they involved the vertebra extensively (5) . Rib lesions were categorized as malignant when they presented as elongated uptake, categorized as benign (fractures) when vertically they involved several ribs. The additional criteria for the CT component of fused SPECT/CT interpretation were that osteolytic lesions without sclerosis and osteoblastic lesions were considered malignant and that sclerotic lesions with spondylophytes and disk space narrowing or in the subchondral region of a joint together with joint space narrowing, subchondral cysts, and osteophytes were considered benign (6).
Clinical and imaging (scintigraphic, CT or MRI) follow-up for at least 6 months (all patients), including tumor markers such as CA 15-3 were used as the reference standard. Increase in the size or changes in the character (osteolytic to sclerotic) during therapy were considered positive for malignancy, whereas lesions with unchanged size and character over 6 months in the absence of treatment were regarded as benign.
Statistical Analysis
A lesion-based analysis was performed. Sensitivity, specificity and accuracy for the diagnosis of malignant or benign bone lesions were calculated using standard statistical formulas for planar BS, SPECT and SPECT/CT. Fisher's exact test was used to determine statistical significance for the comparison of planar BS, SPECT and SPECT/CT. A p value <0.05 was considered as statistically significant.
RESULTS
A total of 72 lesions were evaluated in 23 patients. Four patients had single lesions, four had two lesions, six had three lesions, four had four lesions, four had five lesions and one had six lesions.
These were located in the spine-51, ribs-8, sternum-4, clavicle-2, humerus-1, pelvis-5 and femur- Diagnostic performances of planar BS, SPECT and SPECT/CT are summarized in Table 1 . The sensitivity and specificity for differentiation of benign and malignant bone lesions were 88% and 39% for planar BS, 88% and 85% for SPECT, and 100% and 100% for SPECT/CT on a lesionbased analysis. Sensitivity of SPECT/CT was significantly superior to planar BS and SPECT (p =0.012). Sensitivity of SPECT and planar BS was the same. A specific diagnosis was made with an accuracy of 79% with planar BS, 83% with SPECT, and 100% with SPECT/CT. SPECT/CT was significantly superior to planar BS and SPECT ( p < 0.0001 and p= 0.003, respectively) for specific diagnosis. It was higher (83 % vs 79 %) but not statistically significant when compared between SPECT and planar BS (p = 0.263). However, specificity of SPECT was significantly higher compared with planar BS (p = 0.012). The results provide evidence of a substantial incremental increase in diagnostic accuracy using SPECT/CT over planar imaging or SPECT alone. BS= bone scintigraphy, TP= true-positive, TN = true-negative, FP = false-positive, FN = falsenegative. These trends are consistent with previous research in the cancer population as a whole which has demonstrated reviewers to be significantly more confident in their SPECT/CT diagnoses than those made on planar scintigraphy or SPECT (8, 9) . In a study at the Department of nuclear medicine at University Hospital Zurich, a specific diagnosis was made with planar scintigraphy in 64% of lesions, with SPECT in 86%, and with SPECT/CT in all lesions (9) . This observation is likely to account for the greater improvement reported in this study highlighting the incremental benefit of SPECT/CT over SPECT alone, in comparison with planar bone scintigraphy.
DISCUSSION
SPECT/CT was especially beneficial for the five patients where it resulted in a change of diagnosis. If SPECT/CT had not been included in the imaging protocol for patients in this sample, our results indicate that two false positives and seven false negatives would have occurred.
Clearly there are implications for treatment and prognosis of localized versus metastatic breast cancer. A diagnosis of metastatic disease has profound consequences for the patient, their quality of life and overall survival. The shifts in diagnosis described above and the findings on follow-up suggest the potential effect of SPECT/CT on sensitivity and specificity. There was complete agreement between SPECT/CT and follow-up imaging for 15 lesions in 8 patients. This included the five patients in whom SPECT/CT resulted in a change in diagnosis. Previous work in other patient cohorts supports this finding (4, 10, 11) . Findings on SPECT/CT led to a specific diagnosis in all patients. Often patients with malignant tumors have unclear pain in the skeleton. In theses situations, it does not suffice to rule out metastasis. The cause of benign focal uptake of radiotracer should be evaluated carefully because many underlying diseases can influence treatment. Fused images facilitated the differentiation of benign from metastatic lesion that were difficult to differentiate on scintigraphic scans. Here it was found that fused images were especially useful for differentiating osteoarthritis and spondylarthrosis of the spine. Metastatic foci that represented slight changes and that were overlooked on two separate sets of scintigraphic and CT images could be detected on fused images.
The present study is not without its limitations. This study and results are limited by the relatively small population and the lack of a histologic gold standard. The ideal gold standard for any investigative analysis is the histological confirmation of the findings. We confirmed bone metastasis on the basis of imaging studies and the subsequent clinical course. This is a limitation of this study, but clinical and imaging follow-up for lesions is currently the acceptable gold standard as histological data for all lesions are impractical in these patients. In certain cases it would have been unethical to investigate all detected lesions by invasive procedures, and radiotherapy or chemo radiotherapy was usually started based on criteria, which are routinely used at our institution. Another limitation is related to the retrospective nature of this study and producing an enrollment bias such that only positive bone scan patients were included for SPECT/CT imaging. Further prospective studies in larger numbers of patients are warranted in order to more precisely define its clinical role and accuracy in the detection of bone metastasis.
Cost-benefit analysis is also an essential step to understanding the implications of SPECT/CT for the diagnosis and management of carcinoma of the breast.
In conclusion, the results of the present study indicate that the addition of SPECT/CT resulted in a significant reduction of false-negative reports. A definitive diagnosis was given in the majority of the cases due to the improved diagnostic accuracy compared to planar or SPECT scintigraphy alone in breast cancer patients with suspected bone metastases. When available SPECT/CT is indicated in patients in whom correct interpretation of scintigraphic studies is expected to alter the patient's management.
